Showing 2871-2880 of 5621 results for "".
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Planhttps://modernod.com/news/kala-pharmaceuticals-announces-update-to-kpi-121-0-25-development-plan/2480081/Kala Pharmaceuticals provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease.
- SynergEyes and Brien Holden Vision Institute Join Forces for Specialty Contact Lens Developmenthttps://modernod.com/news/synergeyes-and-brien-holden-vision-institute-join-forces-for-specialty-contact-lens-development/2480098/SynergEyes announced a new partnership with the Brien Holden Vision Institute, a translational vision correction center that delivers advanced, customized vision correction for myopes and presbyopes. The exclusive worldwide licensing agreement will enable the manufacturing of design technologies
- HelpMeSee Eye Surgery Simulator Demonstrations Scheduled for the 2018 World Ophthalmology Conference in Barcelonahttps://modernod.com/news/helpmesee-eye-surgery-simulator-demonstrations-scheduled-for-the-2018-world-ophthalmology-conference-in-barcelona/2480099/HelpMeSee is presenting their Eye Surgery Simulator and companion eBook for teaching manual small incision cataract surgery (MSICS) at the International Council of Ophthalmology’s (ICO) 2018 World Ophthalmology Conference (WOC) in Barcelona, Spain. WOC attendees interested in scheduling dem
- CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa Drug Formulationshttps://modernod.com/news/cms-issues-preliminary-decision-on-unique-j-code-for-avedro-photrexa-drug-formulations/2480101/Avedro announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa drug formulations. Claims submitted with a product specific J code are generally proce
- Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Deliveryhttps://modernod.com/news/eyenovia-receives-notices-of-allowance-from-uspto-on-two-additional-patent-applications-for-ophthalmic-drug-delivery/2480109/Eyenovia announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diameters and velocities, which enable gentle delivery of ophthal
- BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMDhttps://modernod.com/news/biotime-announces-1-9-million-grant-for-continued-development-of-opregen-for-dry-amd/2480136/BioTime has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (IIA). The grant provides funding for the continued development of OpRegen, and to date the IIA has provided annual grants totaling over $13 mil
- First Series C-Round Closing for Medical Device Company Implandata Ophthalmic Productshttps://modernod.com/news/first-series-c-round-closing-for-medical-device-company-implandata-ophthalmic-products/2480150/Ophthalmic medical device company Implandata Ophthalmic Products announced that the company accomplished a first closing of its Series C funding round. The company was able to raise a “mid-single digit million Euro” amount from a strategic and several institutional and private investo
- Novartis CEO Says Drugmaker’s Deal With Trump Lawyer Was a “Mistake”https://modernod.com/news/novartis-ceo-says-drugmakers-deal-with-trump-lawyer-was-a-mistake/2480155/In an internal email sent to employees, Novartis CEO Vasant Narasimhan apologized for the $1.2-million agreement the company made with President Donald Trump’s private lawyer Michael Cohen early last year in a bid to gain insight into US healthcare policy under the new administration. <